NEWS

SSSRI Drug Price Database
Addition of the “Price Maintenance Premium (PMP)” and
Deductible information and Revision of Annual Fees

Analysis of the prevalence of digital therapeutics (DTx) among physicians and the expectations they have
--PatientsMap 2023 Japan version—

PatientsMap 2023 Japan version is now available

PatientsMap 2022 US version now available

PatientsMap 2022 Japan version now available

Analysis by scale of hospitals and cities by the top 10 companies in China in terms of sales rep activities (6 foreign-funded and 4 domestic-funded).

PatientsMap 2022 Japan Survey Begins.

PatientsMap analysis of Chinese physicians’ needs for new drugs

Launch of PatientsMap China 2022

Analysis of trends in the needs for new drugs with PatientsMap data

Increase in symptoms of depression and anxiety worldwide due to COVID-19

Launch of PatientsMap 2017 JP

Market Potential with new product needs in USA

China’s COPD market research report – now available

We welcome HIMA as an SSRI group company

Top unmet medical need: Obesity (US) vs. Dementia (Japan)

Announcement about survey for physicians' survey database "PatientsMap" US version to be conducted

Rare Disease Day 2024
--- Focusing on treatment gaps in rare diseases ---

Analysis of the potential for administering new drugs in terms of the number of patients
- from PatientsMap2022JP version -

Analysis of the potential for administering new drugs in terms of the number of patients
- from PatientsMap2022JP version -

PatientsMap 2022 US version now available

PatientsMap 2022 Japan version now available

Analysis by scale of hospitals and cities by the top 10 companies in China in terms of sales rep activities (6 foreign-funded and 4 domestic-funded).

PatientsMap 2022 Japan Survey Begins.

PatientsMap analysis of Chinese physicians’ needs for new drugs

Launch of PatientsMap China 2022

Final Results of Cyberattack Incident Investigation

PatientsMap database is now available in English. Try out the demo version!

CI Insight Report "Research of China’s COPD Market"

Medical conditions with new product needs: A comparison of US vs. Japan through a large-scale physician survey (PatientsMap) Click here to see the full press release (PDF)

SSRI CHINA completes its investment in HIMA, a Shanghai-based pharmaceutical market research company. Click here to see the full press research (PDF)